Cargando…
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent den...
Autores principales: | Tran, Ngoc Huu, Chansinghakul, Danaya, Chong, Chia Yin, Low, Chian Yong, Shek, Lynette P., Luong, Chan Quang, Fargo, Carina, Wartel, T. Anh, Sun, Sunny, Skipetrova, Anna, Bouckenooghe, Alain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816352/ https://www.ncbi.nlm.nih.gov/pubmed/30724660 http://dx.doi.org/10.1080/21645515.2019.1578595 |
Ejemplares similares
-
Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore
por: Sin Leo, Yee, et al.
Publicado: (2012) -
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021) -
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
por: Carpp, Lindsay N., et al.
Publicado: (2020) -
Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017) -
Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
por: Rosa, Bruno Rodrigues, et al.
Publicado: (2019)